SCHEMBL1005102

SCHEMBL1005102

CC(=NN)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
ALDH1A1 P00352 2/20 0.50
MAPK1 P28482 1/20 0.50
HTT P42858 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ATM Q13315 1/20 0.50
METTL3 Q86U44 1/20 0.50
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
HSD17B10 Q99714 1/20 0.48
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
G6PC1 P35575 1/20 0.45
GAA P10253 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
NFKB1 P19838 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4041540 1.00 LMNA (0.50) LMNAALDH1A1MAPK1HTTL3MBTL1
SCHEMBL3655561 1.00 LMNA (0.50) LMNAALDH1A1MAPK1HTTL3MBTL1
SCHEMBL4149626 0.86 SMN1; SMN2 (0.54) ALDH1A1L3MBTL1CYP1A2CYP2D6HSD17B10
SCHEMBL8720900 0.86 SMN1; SMN2 (0.54) ALDH1A1L3MBTL1CYP1A2CYP2D6HSD17B10
SCHEMBL4279968 0.78 FURIN (0.56) LMNAALDH1A1MAPK1HTTL3MBTL1
SCHEMBL7968589 0.78 FURIN (0.56) LMNAALDH1A1MAPK1HTTL3MBTL1
SCHEMBL4037961 0.78 FURIN (0.56) LMNAALDH1A1MAPK1HTTL3MBTL1
SCHEMBL2067685 0.77 FURIN (0.44) LMNAALDH1A1MAPK1HTTATM
SCHEMBL15053148 0.77 CYP19A1 (0.50) LMNAALDH1A1L3MBTL1POLBMAPT
SCHEMBL2704783 0.77 MEN1 (0.47) LMNAALDH1A1MAPK1HTTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118993945-A Acetophenone hydrazone compound 上海泰初化工技术有限公司 2024-11-22 CN claimed
WO-2023096448-A1 USE OF OBATOCLAX IN TREATING METABOLIC AND FIBROTIC DISEASES 에스케이케미칼 주식회사 2023-06-01 WO claimed
CN-116041345-A Preparation method of compound with optical activity and hydantoin skeleton 温州大学 2023-05-02 CN claimed
WO-2022165382-A1 PHENYLETHYLIDENEHYDRAZINE COMBINATION THERAPIES Neurawell Therapeutics (US) 2022-08-04 WO claimed
WO-2021062048-A2 METHODS AND SYSTEMS FOR MODULATING HEPATIC GABA PRODUCTION OR RELEASE TO ALTER FOOD INTAKE IN MONOGASTRIC SPECIES ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2021-04-01 WO claimed
WO-2020018779-A1 USE OF PHENYLETHYLIDENEHYDRAZINE TO TREAT SEIZURE DISORDERS, DEVELOPMENTAL DISORDERS, NEUROLOGICAL DISORDERS, BEHAVIORAL DISORDERS AND ADDICTION OVID THERAPEUTICS INC. (US) 2020-01-23 WO claimed
US-20190167632-A1 METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) MUELLER WOLFGANG S (US) 2019-06-06 US claimed
US-10123983-B2 DNA methyltransferases for the treatment and prevention of arthritis WASHINGTON UNIVERSITY (US) 2018-11-13 US claimed
US-20170071889-A1 DNA METHYLTRANSFERASES FOR THE TREATMENT AND PREVENTION OF ARTHRITIS WASHINGTON UNIVERSITY 2017-03-16 US claimed
EP-2593104-A2 METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) Müller, Prof. Dr., Wolfgang (DE) 2013-05-22 EP claimed
US-20120115919-A1 METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) THE REGENTS OF THE UNIVERSITY OF NEW MEXICO 2012-05-10 US claimed
WO-2011011692-A2 METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) STC.UNM (US) 2011-01-27 WO claimed
US-20050080260-A1 Preparation of prodrugs for selective drug delivery LUMINIDE 2005-04-14 US claimed
CN-116041345-B Preparation method of compound with optical activity and hydantoin skeleton 温州大学 2025-10-03 CN disclosed
US-20250082589-A1 PHENYLETHYLIDENEHYDRAZINE DIMERS AND METHODS OF USING SAME Neurawell Therapeutics (US) 2025-03-13 US disclosed
US-20250082589-A1 PHENYLETHYLIDENEHYDRAZINE DIMERS AND METHODS OF USING SAME Neurawell Therapeutics (US) 2025-03-13 US disclosed
EP-0097620-A2 Heat or pressure sensitive registration material CIBA-GEIGY AG (CH) 1984-01-04 EP disclosed
EP-0006693-A1 N-substituted trialkylstannylhydrocarbylcarboxylic acid hydrazides, methods of their preparation and insecticide compositions containing them UNIROYAL, INC. (US) 1980-01-09 EP disclosed
US-4178382-A INSECTICIDE FOR COTTON UNIROYAL, INC. (US) 1979-12-11 US disclosed
US-4016157-A COLORING PLASTICS AND LACQUERS CIBA-GEIGY CORPORATION (US) 1977-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080260-A1 Preparation of prodrugs for selective drug delivery APEH, PAH, ALAD LMNA 939/4885ALDH1A1 61/4885MAPK1 3847/4885
US-20250082589-A1 PHENYLETHYLIDENEHYDRAZINE DIMERS AND METHODS OF USING SAME PNMT, DRD4, HTR5A LMNA 4398/4885ALDH1A1 1225/4885MAPK1 4306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.